Paul Bolno, Wave Life Sciences CEO (via Twitter)

Wave crash­es — again — as 2 more drugs go down to de­feat, this time for Hunt­ing­ton's

Just sev­en days ago Roche threw in the tow­el on their an­ti­sense drug for Hunt­ing­ton’s. Now we’re learn­ing that a close­ly-watched an­ti­sense oligonu­cleotide pro­gram in the hands of Wave Life Sci­ences $WVE crashed in an ear­ly-stage study — wip­ing out two ex­per­i­men­tal drug can­di­dates and forc­ing the biotech to turn to a back-up ap­proach while watch­ing shares crater.

WVE-120102 failed to sep­a­rate from place­bo in im­pact on mu­tant Hunt­ingtin pro­tein at any of the dos­es giv­en to Hunt­ing­ton’s pa­tients. And a sep­a­rate, small­er study showed on­ly an in­con­sis­tent hit on mHTT that in­di­cat­ed they were on a one-way track to fail­ure with the drug.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.